Skip to main content
. 2023 Aug 3;12:e79548. doi: 10.7554/eLife.79548

Appendix 2—table 37. Antidiabetic Cohort (Region=New York State), Patient Characteristics Pre/Post Match.

Region=NY by Antidiabetic Use: Unmatched Region=NY by Antidiabetic Use: Matched
All DIAB Non-users DIAB Users p-value All DIAB Non-users DIAB Users p-value
N % N % N % N % N % N %
All Patients 968,296 100.0% 863,179 89.1% 105,117 10.9% 209,382 100.0% 104,691 50.0% 104,691 50.0%
Age
≤20 133,178 13.8% 132,723 15.4% 455 0.4% <0.001 910 0.4% 455 0.4% 455 0.4% 1.00
21-40 192,959 19.9% 186,785 21.6% 6,174 5.9% 12,328 5.9% 6,164 5.9% 6,164 5.9%
41-50 127,794 13.2% 117,342 13.6% 10,452 9.9% 20,880 10.0% 10,440 10.0% 10,440 10.0%
51-60 172,444 17.8% 148,040 17.2% 24,404 23.2% 48,735 23.3% 24,369 23.3% 24,366 23.3%
61-70 159,912 16.5% 130,968 15.2% 28,944 27.5% 57,638 27.5% 28,819 27.5% 28,819 27.5%
71-80 120,117 12.4% 95,621 11.1% 24,496 23.3% 48,625 23.2% 24,311 23.2% 24,314 23.2%
≥81 61,892 6.4% 51,700 6.0% 10,192 9.7% 20,266 9.7% 10,133 9.7% 10,133 9.7%
Gender
Female 573,610 59.2% 512,889 59.4% 60,721 57.8% <0.001 120,937 57.8% 60,467 57.8% 60,470 57.8% 0.99
Male 394,686 40.8% 350,290 40.6% 44,396 42.2% 88,445 42.2% 44,224 42.2% 44,221 42.2%
Insurance
Commercial 500,918 51.7% 468,804 54.3% 32,114 30.6% <0.001 64,200 30.7% 32,100 30.7% 32,100 30.7% 1.00
Dual 6,814 0.7% 4,408 0.5% 2,406 2.3% 4,389 2.1% 2,196 2.1% 2,193 2.1%
Medicaid 252,366 26.1% 224,334 26.0% 28,032 26.7% 55,853 26.7% 27,925 26.7% 27,928 26.7%
Medicare 208,198 21.5% 165,633 19.2% 42,565 40.5% 84,940 40.6% 42,470 40.6% 42,470 40.6%
PCP Visit 2019
No 521,282 53.8% 484,071 56.1% 37,211 35.4% <0.001 74,215 35.4% 37,106 35.4% 37,109 35.4% 0.99
Yes 447,014 46.2% 379,108 43.9% 67,906 64.6% 135,167 64.6% 67,585 64.6% 67,582 64.6%
Continuous Outcomes
mean SD mean SD mean SD p-value mean SD mean SD mean SD p-value
CCI 0.65 1.39 0.56 1.30 1.34 1.84 <0.001 1.32 1.79 1.32 1.79 1.32 1.79 0.98

CCI: Charlson Comorbidity Index; DIAB: antidiabetic; PCP: primary care physician; SD: standard deviation.